Record mula sa primary source
Decision-gradeTopline na resulta
Cullinan: nakaplano ang autoimmune data readouts ng CLN-978 sa Q2 hanggang Q4 2026
Inihayag ng kumpanya na ang paunang single-dose data mula sa OUTRACE RA at OUTRACE SLE studies ay ibabahagi sa Q2 2026, kasama ang repeat-dosing data mula sa RA na inaasahan sa Q3 2026 at Sjögren’s data sa Q4 2026. Ang mga readouts na ito ang magiging unang company-sponsored clinical data para sa isang CD19 T-cell engager sa autoimmune indications.
Mahahalagang fact
- Na-file
- Ene 8, 2026, 12:15 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
CGEMCullinan- Asset
- CLN-978
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026 Preliminary cash and investments of $439.0 million as of December 31, 2025; Runway into 2029 CAMBRIDGE, Mass. January 8, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “C